Specifically, these studies utilized adoptive immunotherapy using T cell receptors (TCRs) targeting MART-1, a known melanoma-associated antigen, which resulted in sensorineural hearing loss that in some cases was ameliorated by local steroid administration (Johnson et al., 2009). The gene discussed is MLANA; the disease is melanoma.